ALCHEMIA REPORTS NET LOSS OF $15.8M

ALCHEMIA REPORTS NET LOSS OF $15.8M

BRISBANE biotech company Alchemia (ASX:ACL) has reported a net loss of $15.8 million for the first half of the 2015 financial year, compared to $5.5 million for the six months ending 31 December 2013.

A contributing factor of this result was the failure of its recent cancer drug trial.

The pivotal phase three clinical trial of HA-Irinotecan in metastatic colorectal cancer failed to reach its primary endpoint in significant improvement in progression free survival and did not meet its secondary endpoint of an improvement in overall-survival.

This led to shares dropping by 83 per cent from 51.5 cents to 10.5 cents, in November 2014. 

Since the announcement of the above results, ACL has undergone a strategic review of all its assets and operations.

In addition, ACL has recorded profit share income arising from sales of fondaparinux - a collaboration agreement with Dr Reddy's Laboratories - of $2.8 million for the period and had net assets of $11.6 million.

In addition, operating expenditure of $24.9 million increased by $14.2 million over the corresponding period.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Advertisement

Related Stories

Woolies exec Paul Graham named new Australia Post CEO

Woolies exec Paul Graham named new Australia Post CEO

Woolworths (ASX: WOW) chief supply chain officer Paul Graham has ...

Quarantine-free travel to WA effective for all Australian states from 19 April

Quarantine-free travel to WA effective for all Australian states from 19 April

Western Australia will soon be able to welcome any interstate tr...

Australia strikes deal with Pfizer to double vaccine intake to 40 million

Australia strikes deal with Pfizer to double vaccine intake to 40 million

The Australian Government has reached a deal with Pfizer overnigh...

Australia's largest floral wholesaler Lynch Group buds on the ASX

Australia's largest floral wholesaler Lynch Group buds on the ASX

An Australian company that has been growing and wholesaling flowe...